Jump to content
RemedySpot.com

New clinical trial announced - NCCTG

Rate this topic

Guest guest

By Guest guest
in Health, Medicine and Natural Healing 11

 Share

Recommended Posts

Guest guest

Guest guest

Posted
Posted

MK2206, Bendamustine, and Rituximab in Treating Patients

With Relapsed Chronic Lymphocytic Leukemia or Small

Lymphocytic Lymphoma

MK2206 is an an allosteric Akt Inhibitor that is downstream

in the signal pathway of PI3K. Akt lies at a critical

signaling node important in promoting cell survival and

inhibiting apoptosis.

The clinical trial is not yet receiving patients

Phase I - NCT01369849

PI - Wei Ding, MBBS, PhD NCCTG Mayo Clinic, Rochester MN

Link: http://clinicaltrials.gov/ct2/show/NCT01369849

CLL CANADA

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
 Share
Go to topic listing
×
×
  • Create New...